scholarly journals Age disparities in lung cancer survival in New Zealand: the role of patient and clinical factors

2020 ◽  
Author(s):  
Sophie Pilleron ◽  
Camille Maringe ◽  
Hadrien Charvat ◽  
June Atkinson ◽  
Eva Morris ◽  
...  
Keyword(s):  
Lung Cancer ◽  
New Zealand ◽  
Cancer Survival ◽  
Age Difference ◽  
Stage At Diagnosis ◽  
Clinical Factors ◽  
Emergency Presentation ◽  
Age Disparities ◽  
Lung Cancer Survival

AbstractBackgroundAge is an important prognostic factor for lung cancer. However, no studies have investigated the age difference in lung cancer survival per se. We, therefore, described the role of patient-related and clinical factors on the age pattern in lung cancer excess mortality hazard by stage at diagnosis in New Zealand.MethodsWe extracted 22 487 new lung cancer cases aged 50-99 (median age = 71, 47.1% females) diagnosed between 1 January 2006 and 31 July 2017 from the New Zealand population-based cancer registry and followed up to December 2019. We modelled the effect of age at diagnosis, sex, ethnicity, deprivation, comorbidity, and emergency presentation on the excess mortality hazard by stage at diagnosis, and we derived corresponding lung cancer net survival.ResultsThe age difference in net survival was particularly marked for localised and regional lung cancers, with a sharp decline in survival from the age of 70. No identified factors influenced age disparities in patients with localised cancer. However, for other stages, females had a greater age difference in survival between middle-aged and older patients with lung cancer than males. Comorbidity and emergency presentation played a minor role. Ethnicity and deprivation did not influence age disparities in lung cancer survival.ConclusionSex and stage at diagnosis were the most important factors of age disparities in lung cancer survival in New Zealand.Key messagesWhat is the key question?How do patient-related and clinical factors influence age pattern in lung cancer survival?What is the bottom line?Age disparities in lung cancer survival were strongest for females and non-advanced disease. Deprivation, ethnicity, comorbidity, and emergency presentation did not influence age disparities.Why read on?Our findings reinforce the call for a better representation of older adults in clinical trials and a wider use of geriatric assessment to identify patients who will benefit treatment.

scholarly journals Age disparities in lung cancer survival in New Zealand: the role of patient and clinical factors

Lung Cancer ◽  
2021 ◽  
Author(s):  
Sophie Pilleron ◽  
Camille Maringe ◽  
Hadrien Charvat ◽  
June Atkinson ◽  
Eva Morris ◽  
...  
Keyword(s):  
Lung Cancer ◽  
New Zealand ◽  
Cancer Survival ◽  
Clinical Factors ◽  
Age Disparities ◽  
Lung Cancer Survival

scholarly journals Lung cancer survival trend in Umbria, Italy, 1994-2016: preliminary results

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
A Ostorero ◽  
A Gili ◽  
S Violi ◽  
F Stracci
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Tobacco Smoking ◽  
Cancer Survival ◽  
Cancer Control ◽  
Mortality Trends ◽  
Incidence And Mortality ◽  
New Treatments ◽  
Lung Cancer Survival

Abstract Background Lung cancer is the second most common cancer worldwide and the leading cause of death for cancer (18.4%). During the last 30 years, lung cancer incidence and mortality increased in women and decreased in men, because of tobacco smoking exposure. Population survival trend reflects both the influence of disease severity at diagnosis and treatment effectiveness. Some studies reported an increase in global lung cancer survival and linked it to new treatment options. However, change in the overall survival may also reflect a shift towards morphologies with more favorable prognosis. We analyzed overall and morphology specific survival trends for lung cancer to gain insight on the role of new treatments and changing exposures. Methods We analyzed lung cancer 1 y-survival and 3 y-survival after diagnosis in Umbria (890'000 inhabitants) in the period 1994-2016. Population-based data were obtained from the Umbrian Cancer Registry (RTUP), Italy. We estimated relative net survival (Pohar-Perme approach) stratified both for sex and histotype (NSCLC, SCLC, NOS), considering six diagnostic periods from 1994 to 2016 (4 years for period, except 3 in the last one) for 5'268 lung cancer cases (26% women). Results Overall survival by gender resulted 40,5% (1y) and 16.5% (3y) in men, 47,3% (1y) and 23,2% (3y) in women. NSCLC survival increased in women during the period 1994-2016 from 41% to 53% (1y) and from 23% to 33% (3y), and remained unchanged in men. SCLC 3 year-survival did not change significantly neither in women nor in men. Conclusions We did not observe a significant increase in lung cancer survival over a 25 years period. We observed a significant increase in survival probabilities for NSCLC among women only. Thus, our data don't confirm a major role of new treatments in improving lung cancer control. We will provide further analyses for adenocarcinoma and a comparison of incidence and mortality trends to understand the influence of exposures and treatments on survival. Key messages A general increase in lung cancer survival, as could be expected after the introduction of new highly effective treatments is not present in western countries. Reducing exposure to tobacco smoking and environmental pollution remain the main intervention to improve lung cancer control.

The role of glutathione-related genes in lung cancer survival

Lung Cancer ◽  
1999 ◽  
Vol 25 ◽  
pp. S14
Author(s):  
P. Yang ◽  
A. Yokomizo ◽  
R. Marks ◽  
T. Lesnick ◽  
J. Sloan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Survival ◽  
Lung Cancer Survival

scholarly journals Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival

2020 ◽  
Vol 12 (9) ◽  
pp. 5086-5095
Author(s):  
Idoroenyi Amanam ◽  
Isa Mambetsariev ◽  
Rohan Gupta ◽  
Srisairam Achuthan ◽  
Yingyu Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cancer Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Survival

scholarly journals Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007

Thorax ◽  
2013 ◽  
Vol 68 (6) ◽  
pp. 551-564 ◽  
Author(s):  
Sarah Walters ◽  
Camille Maringe ◽  
Michel P Coleman ◽  
Michael D Peake ◽  
John Butler ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Survival ◽  
Population Based ◽  
Stage At Diagnosis ◽  
Population Based Study ◽  
The Uk ◽  
Lung Cancer Survival

scholarly journals International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study

Thorax ◽  
2021 ◽  
pp. thoraxjnl-2020-216555
Author(s):  
Marzieh Araghi ◽  
Miranda Fidler-Benaoudia ◽  
Melina Arnold ◽  
Mark Rutherford ◽  
Aude Bardot ◽  
...  
Keyword(s):  
Lung Cancer ◽  
New Zealand ◽  
Cancer Survival ◽  
Small Cell ◽  
Histological Type ◽  
Stage At Diagnosis ◽  
International Differences ◽  
One Year ◽  
The Uk ◽  
Survival Differences

IntroductionLung cancer has a poor prognosis that varies internationally when assessed by the two major histological subgroups (non-small cell (NSCLC) and small cell (SCLC)).Method236 114 NSCLC and 43 167 SCLC cases diagnosed during 2010–2014 in Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK were included in the analyses. One-year and 3-year age-standardised net survival (NS) was estimated by sex, histological type, stage and country.ResultsOne-year and 3-year NS was consistently higher for Canada and Norway, and lower for the UK, New Zealand and Ireland, irrespective of stage at diagnosis. Three-year NS for NSCLC ranged from 19.7% for the UK to 27.1% for Canada for men and was consistently higher for women (25.3% in the UK; 35.0% in Canada) partly because men were diagnosed at more advanced stages. International differences in survival for NSCLC were largest for regional stage and smallest at the advanced stage. For SCLC, 3-year NS also showed a clear female advantage with the highest being for Canada (13.8% for women; 9.1% for men) and Norway (12.8% for women; 9.7% for men).ConclusionDistribution of stage at diagnosis among lung cancer cases differed by sex, histological subtype and country, which may partly explain observed survival differences. Yet, survival differences were also observed within stages, suggesting that quality of treatment, healthcare system factors and prevalence of comorbid conditions may also influence survival. Other possible explanations include differences in data collection practice, as well as differences in histological verification, staging and coding across jurisdictions.

scholarly journals Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review

2020 ◽  
Author(s):  
Sophie Pilleron ◽  
Helen Gower ◽  
Maryska Janssen-Hejnen ◽  
Virginia Signal ◽  
Jason Gurney ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Survival ◽  
Economic Status ◽  
Population Based ◽  
Poor Quality ◽  
Absolute Difference ◽  
Cancer Site ◽  
Age Disparities ◽  
Advanced Stages ◽  
Lung Cancer Survival

Objective: To identify patterns of age disparities in cancer survival, using colon and lung cancer as exemplars. Methods: We conducted a systematic review of literature published in EMBASE, MEDLINE, Scopus, and Web of Science according to PRISMA guidelines. We included population-based studies in patients with colon or lung cancer. We assessed the quality of included studies against selected evaluation domains from the QUIPS Tool, and items concerning statistical reporting. We evaluated age disparities using the absolute difference in survival or mortality rates between middle-aged group and the oldest age group, or by describing survival curves. Results: Out of 2,162 references reviewed, we retained 35 studies (15 for colon, 18 for lung, 2 for both sites). Regardless of the cancer site, included studies were highly heterogeneous and often of poor quality. The magnitude of age disparities in survival varied greatly by sex, ethnicity, socio-economic status, stage at diagnosis, cancer site and morphology, the number of nodes examined, and by treatment strategy. Although results were inconsistent for most characteristics, we consistently observed greater age disparities for females with lung cancer compared to males. Also, age disparities increased with more advanced stages for colon cancer and decreased with more advanced stages for lung cancer. Conclusions: Although age is one of the most important prognostic factors in cancer survival, age disparities in colon and lung cancer survival have so far been understudied in population-based research. Further studies are needed to better understand age disparities in colon and lung cancer survival. (PROSPERO registration number: CRD42020151402).

scholarly journals Impact of low-dose CT screening for lung cancer on ethnic health inequities in New Zealand: a cost-effectiveness analysis

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e037145
Author(s):  
Melissa McLeod ◽  
Peter Sandiford ◽  
Giorgi Kvizhinadze ◽  
Karen Bartholomew ◽  
Sue Crengle
Keyword(s):  
Lung Cancer ◽  
New Zealand ◽  
Cost Effectiveness ◽  
Low Dose ◽  
Total Population ◽  
Cancer Survival ◽  
Screening Programme ◽  
Cost Effective ◽  
Health Gains ◽  
Lung Cancer Survival

ObjectiveThere are large inequities in the lung cancer burden for the Indigenous Māori population of New Zealand. We model the potential lifetime health gains, equity impacts and cost-effectiveness of a national low-dose CT (LDCT) screening programme for lung cancer in smokers aged 55–74 years with a 30 pack-year history, and for formers smokers who have quit within the last 15 years.DesignA Markov macrosimulation model estimated: health benefits (health-adjusted life-years (HALYs)), costs and cost-effectiveness of biennial LDCT screening. Input parameters came from literature and NZ-linked health datasets.SettingNew Zealand.ParticipantsPopulation aged 55–74 years in 2011.InterventionsBiennial LDCT screening for lung cancer compared with usual care.Outcome measuresIncremental cost-effectiveness ratios were calculated using the average difference in costs and HALYs between the screened and the unscreened populations. Equity analyses included substituting non-Māori values for Māori values of background morbidity, mortality and stage-specific survival. Changes in inequities in lung cancer survival and ‘health-adjusted life expectancy’ (HALE) were measured.ResultsLDCT screening in NZ is likely to be cost-effective for the total population: NZ$34 400 per HALY gained (95% uncertainty interval NZ$27 500 to NZ$42 900) and for Māori separately (using a threshold of gross domestic product per capita NZ$45 000). Health gains per capita for Māori females were twice that for non-Māori females and 25% greater for Māori males compared with non-Māori males. LDCT screening will narrow absolute inequities in HALE and lung cancer mortality for Māori, but will slightly increase relative inequities in mortality from lung cancer (compared with non-Māori) due to differential stage-specific survival.ConclusionA national biennial LDCT lung cancer screening programme in New Zealand is likely to be cost-effective, will improve total population health and reduce health inequities for Māori. Attention must be paid to addressing ethnic inequities in stage-specific lung cancer survival.

Sign in / Sign up

Export Citation Format

Share Document